CalciMedica, Inc. (NASDAQ:CALC) Sees Significant Decline in Short Interest

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 34,200 shares, a decrease of 9.3% from the September 30th total of 37,700 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily volume of 35,500 shares, the short-interest ratio is currently 1.0 days.

Analyst Upgrades and Downgrades

CALC has been the topic of several recent analyst reports. Oppenheimer lifted their price objective on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, July 10th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of CalciMedica in a research report on Tuesday, August 13th.

Insiders Place Their Bets

In other news, Director Robert N. Wilson purchased 54,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was bought at an average price of $3.72 per share, with a total value of $200,880.00. Following the acquisition, the director now directly owns 364,196 shares of the company’s stock, valued at approximately $1,354,809.12. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have bought 65,000 shares of company stock worth $243,120. Company insiders own 41.55% of the company’s stock.

CalciMedica Stock Performance

CalciMedica stock traded down $0.10 during midday trading on Friday, reaching $3.60. 164,765 shares of the company’s stock were exchanged, compared to its average volume of 34,053. The stock’s 50-day simple moving average is $4.27 and its 200 day simple moving average is $4.64. The firm has a market cap of $38.70 million, a price-to-earnings ratio of -2.58 and a beta of 1.27. CalciMedica has a 52 week low of $2.14 and a 52 week high of $8.38.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Research analysts forecast that CalciMedica will post -2.21 earnings per share for the current year.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.